Diphtheria Market Report 2026

Diphtheria Market Overview

• Diphtheria market size has reached to $9.39 billion in 2025 • Expected to grow to $13.05 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Rising Prevalence Of Bacterial Infections Fuels Growth In The Diphtheria Market • Market Trend: Thermostable Diphtheria Toxoid Vaccines Improve Accessibility And Immunisation Coverage In Remote Regions • Asia-Pacific was the largest region in 2025.

What Is Covered Under Diphtheria Market?

Diphtheria is a bacterial illness caused by strains of bacteria called bacteria Corynebacterium diphtheriae which make a toxin that predominantly affects the mucous membranes of the throat and nose and can also affect other regions of the body in severe instances. It can be identified by throat discomfort, weakness, fever, swollen neck glands, breathing difficulties due to tissues clogging the nose and throat and difficulty in swallowing. The main types of infection related to diphtheria are diphtheria, skin diphtheria and others. Diphtheria is a dangerous bacterial infection that can infect the tonsils, nose, throat and/or skin, which is caused by toxin-producing bacteria called Corynebacterium diphtheriae. The various diagnosis involved are physical examination, throat culture and others diagnosed with antibiotics, antitoxin and others. The various distribution channels are hospital pharmacies, online pharmacies and retail pharmacies used in hospitals, homecare, specialty clinics and others.

What Is The Diphtheria Market Growth Forecast?

The diphtheria market size is expected to see strong growth in the next few years. It will grow to $13.05 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to global immunization campaigns, improved diagnostic access, public health funding, disease surveillance digitization, outbreak preparedness programs. Major trends in the forecast period include continued demand for vaccination and immunization programs, increased focus on early diagnosis and surveillance, growing use of antibiotic and antitoxin therapies, expansion of public health awareness initiatives, strengthening of infectious disease monitoring systems.

Global Diphtheria Market Segmentation

1) By Type: Diphtheria, Skin Diphtheria, Other Types 2) By Diagnosis: Physical Examination, Throat Culture, Other Diagnosis 3) By Treatment: Antibiotics, Antitoxin, Other Treatments 4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy 5) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Diphtheria: Respiratory Diphtheria, Non-respiratory Diphtheria 2) By Skin Diphtheria: Cutaneous Diphtheria 3) By Other Types: Diphtheritic Myocarditis, Diphtheritic Neuritis

What Is The Driver Of The Diphtheria Market?

The rising prevalence of bacterial infections is expected to propel the growth of the diphtheria market going forward. A bacterial infection is a sickness or condition attributed to bacterial growth or the toxins produced by bacteria that invade the body. Diphtheria is a serious infection caused by bacteria strains that suppress the immune system and promote the proliferation of Corynebacterium diphtheria. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the number of tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing a rise of 1,295 cases. Therefore, the rising prevalence of bacterial infections will drive the diphtheria industry.

Key Players In The Global Diphtheria Market

Major companies operating in the diphtheria market are Sanofi Pasteur, GlaxoSmithKline plc, Serum Institute of India Pvt Ltd, Biological E Limited, Bharat Biotech International Limited, Panacea Biotec Ltd, Mitsubishi Tanabe Pharma Corporation, KM Biologics (Meiji Holdings), AJ Vaccines, Bionet‑Asia, Wuhan Institute of Biological Products, Walvax Biotechnology Co Ltd, Chengdu Institute of Biological Products Co Ltd, Minhai Biotechnology, Bio Farma Persero, Indian Immunologicals Ltd, LG Chem Ltd, Astellas Pharma Inc, Takeda Pharmaceutical Company Limited, MassBiologics, Shanghai Institute of Biological Products Co Ltd, Changchun Institute of Biological Products Co Ltd, Hualan Biological Engineering Inc, Valneva SE, Pasteur Institute of India, Beijing Tiantan Biological Products Co Ltd, Chongqing Zhifei Biological Products Co Ltd, Shenzhen Kangtai Biological Products Co Ltd.

Global Diphtheria Market Trends and Insights

Major companies operating in the diphtheria market are focusing on incorporating advanced formulation trends such as thermostabilisation technology to enhance distribution efficiency, temperature-resilience, and cold-chain independence. Thermostabilisation technologies are advanced formulation methods that protect vaccine antigens from degradation caused by heat or temperature fluctuations, enabling capabilities such as room-temperature stability, reduced product wastage, and improved last-mile delivery. For instance, in April 2025, Stablepharma Ltd, a UK-based biotechnology company, entered Phase 1 clinical trials with SPVX02, a fridge-free tetanus–diphtheria vaccine designed to maintain potency after exposure to temperature cycles ranging from −20°C to +40°C and provide up to 18 months of room-temperature shelf life, featuring heat-resilient antigen preservation and cold-chain-free deployment potential. SPVX02 improves vaccine stability, supply-chain reliability, and access in low-infrastructure regions.

What Are Latest Mergers And Acquisitions In The Diphtheria Market?

In June 2025, BioNet, a Thailand-based vaccine biotechnology company, partnered with PT Bio Farma (Persero) to expand access to a next-generation TdaP vaccine across ASEAN markets. With this partnership, BioNet and Bio Farma aim to combine BioNet’s recombinant pertussis technology with Bio Farma’s large-scale manufacturing capabilities to broaden regional immunisation coverage, improve vaccine availability for key population groups, and support long-term self-sufficiency in Southeast Asia’s vaccine supply ecosystem. PT Bio Farma (Persero) is an Indonesia-based state-owned vaccine manufacturer that supplies a wide portfolio of routine immunisation vaccines.

Regional Outlook

Asia-Pacific was the largest region in the diphtheria market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Diphtheria Market?

The diphtheria market consists of revenues earned by entities by providing services such as consultation, diagnosis and treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The diphtheria market also includes the sales of medications such as vaccines, antibiotics and antitoxins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Diphtheria Market Report 2026?

The diphtheria market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the diphtheria industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.